We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Roquefort Therapeutics Plc | LSE:ROQ | London | Ordinary Share | GB00BMDQ2T15 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.40 | 92,993 | 08:00:17 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 4.30 | 4.50 | 4.40 | 4.40 | 4.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Cmp Integrated Sys Design | 200k | -1.75M | -0.0135 | -3.26 | 5.68M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:49:34 | O | 23,317 | 4.34 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 27/6/2024 | 12:46 | UK RNS | Roquefort Therapeutics PLC Results of AGM |
| 20/6/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Appointment of Broker |
| 04/6/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Notice of Annual General Meeting |
| 23/5/2024 | 21:25 | ALNC |  TRADING UPDATES: Windward wins deal; Kodal progresses at Bougouni |
| 23/5/2024 | 07:05 | UK RNS | Roquefort Therapeutics PLC Issue of Convertible Loan Notes & Board Changes |
| 23/5/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Midkine Antibody Licencing Deal |
| 26/4/2024 | 20:59 | ALNC | EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany |
| 26/4/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Annual Report & Financial Statements - 31 Dec.. |
| 05/4/2024 | 12:32 | ALNC | IN BRIEF: Roquefort cancels fundraise after "unusual" stock movements |
| 05/4/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Response to Share Price Movement |
Roquefort Therapeutics (ROQ) Share Charts1 Year Roquefort Therapeutics Chart |
|
1 Month Roquefort Therapeutics Chart |
Intraday Roquefort Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/6/2024 | 22:13 | Roquefort Therapeutics plc targeting cancer | 24 |
| 26/5/2024 | 09:03 | Roquefort a potentially exploding 2022 bio tech stock.... | 164 |
| 22/12/2021 | 13:19 | ROQ - Watch the pumpers | 36 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 13:49:35 | 4.34 | 23,317 | 1,011.96 | O |
| 2024-07-26 13:27:19 | 4.34 | 23,317 | 1,011.96 | O |
| 2024-07-26 07:00:52 | 4.34 | 46,359 | 2,011.98 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Roquefort Therapeutics Daily Update Roquefort Therapeutics Plc is listed in the Cmp Integrated Sys Design sector of the London Stock Exchange with ticker ROQ. The last closing price for Roquefort Therapeutics was 4.40p.Roquefort Therapeutics currently has 129,149,998 shares in issue. The market capitalisation of Roquefort Therapeutics is £5,682,600. Roquefort Therapeutics has a price to earnings ratio (PE ratio) of -3.26. This morning ROQ shares opened at 4.40p |
Posted at 01/6/2024 11:20 by z1co WOWpurple is the biggest clown on the advfn forums Get a life troll , you're just a 2 bit trader that buys after me. Share price will take off upon further news regarding the deal , the company will soon receive upfront payment of between $1.25m and $2.5m. Yesterday there were lots of buys sub 5p including mine. |
Posted at 30/5/2024 19:45 by z1co Share price consolidating above 5p before further gains on more positive news flow regarding last weeks licencing deal and further new deals in H2.The company will receive an initial upfront payment of between $1.25m - $2.5m. The shares of this small cap (mkt cap less than £7) biotech company focused on developing first in class medicines in the high value and high growth oncology market have huge potential to multibag. |
Posted at 27/5/2024 10:34 by z1co !FOLLOWFEEDRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines The highly complementary profile of five best-in-class medicines consists of:- Midkine antibodies with significant in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumours; STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. ++++++++++++++++++++ 23/05/2024: Midkine Antibody Licencing Deal A summary of the agreed commercial terms in the term sheet are listed below: · Initial consideration value of US$10 million, which includes non-dilutive equity in the SPV; · Exclusive worldwide licence granted to the SPV for 20 years; · Within 3 years, PDC to develop at least one of the Midkine antibodies within the SPV to the completion of a Phase 1 trial and then, upon success, to complete a trade sale of the SPV; and · Roquefort Therapeutics will receive circa 24% from any successful trade sale proceeds, which if the Phase 1 trial is successful, this 24% is projected to be worth up to US$50M (gross) based on similar phase 1 trade sales. Ajan Reginald, Roquefort Therapeutics CEO commented: "We are pleased to announce this therapeutic licencing deal with an initial payment which is likely to include $1.25-2.5M upfront and a 24% share of what is substantial potential upside. ++++++++++++++++++++ CEO speaking after the licencing deal last week: ++++++++++++++++++++ . |
Posted at 24/5/2024 14:02 by z1co Share price will likely to consolidate above 5p before further gains on more positive news flow from yesterday's licencing and further deals in H2.CEO's comments from yesterday's rns: We expect to conclude this licensing agreement as soon as possible. Roquefort Therapeutics is now working with PDC to complete due diligence and has commenced the drafting of the definitive licence agreement. Further updates will be provided by the Company as this progresses and becomes binding. In the meantime, we remain focused on completing the other licencing deals that we are negotiating and look forward to updating the market in due course. We expect to complete additional and potentially larger transactions in the second half of this year. |
Posted at 23/5/2024 16:03 by z1co Roquefort Therapeutics leaps on news term sheet for licencing deal with PDC23-05-2024 Shares of UK immune-oncology company Roquefort Therapeutics (LSE: ROQ) rose almost 24% to 5.51 pence this morning, following the signing of a term sheet to out-license its Midkine antibody portfolio to Dubai-based PDC. PDC is a leading MEA pharmaceutical research and development organization which has conducted over 150 clinical trials. This is a strategic out-licencing deal in which Roquefort Therapeutics receives $10 million total initial consideration&hellip |
Posted at 23/5/2024 10:25 by z1co Today is not even a spike , the shares were trading above 9p not so long ago and the funding concerns dropped the price to the current lows.Share price will start to rise back towards the 9p plus level. |
Posted at 23/5/2024 09:35 by z1co From the Proactive article:Following a successful trial, the SPV will be sold, with Roquefort earning around 24% of the sale proceeds. This share could be worth up to $50 million based on similar phase I trade sales, Roquefort said. |
Posted at 23/5/2024 09:27 by z1co ttps://www.proactiveRoquefort Therapeutics signs out-licensing term sheet potentially worth an initial $10m Published: 07:24 23 May 2024 BST Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said it has signed a term sheet to out-license its Midkine antibody portfolio to Dubai-based contract research group PDC, which would include an upfront sum of $10 million. The immuno-oncology group also expects to receive a non-dilutive equity stake in a special purpose vehicle (SPV) that PDC will use to develop the Midkine antibodies. The exclusive worldwide licence will last for 20 years. Within three years, PDC aims to have completed a phase I clinical trial for at least one of the antibodies. Following a successful trial, the SPV will be sold, with Roquefort earning around 24% of the sale proceeds. This share could be worth up to $50 million based on similar phase I trade sales, Roquefort said. "PDC is a great partner with a strong track record of completing clinical trials and we are confident they will accelerate the development of the Midkine antibodies into the clinic," added CEO Ajan Reginal. "Upon a successful phase I exit, this would create significant returns to the SPV shareholders. We believe this is a good deal for all parties and it validates our business model and highlights our deal-making capabilities. We expect to conclude this licensing agreement as soon as possible." The term sheet runs until December 31, allowing PDC to complete its due diligence. In a separate announcement, Roquefort said it is raising a gross £655,000 via the issue of unsecured convertible loan notes, which, along with current cash resources and cost-cutting measures, provides a funding runway for at least the next 12 months. Investors were also told Professor Sir Martin Evans will move from the role of chief scientific officer to become a non-executive director. Having completed his tenure as a non-exec, Dr Michael Stein will step down from the Roquefort board and will be replaced in 'due course'. |
Posted at 05/4/2024 07:42 by apotheki Response to Share Price MovementRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, notes recent bulletin board speculation about a placing that the Company may be undertaking. The Company recently engaged its advisers to commence a process of market soundings in relation to a potential fundraise. However, in response to incorrect bulletin board comments regarding a speculative placing price and resulting unusual share price movements, the Board has decided to not proceed with any potential placing at this time. As previously announced, Roquefort Therapeutics remains focused on completing an out-licensing agreement during the course of 2024 with potential Big Pharma partners and will update the market when a binding agreement is entered into. |
Posted at 24/1/2023 08:00 by the chairman elect Roquefort Therapeutics plc / LSE:ROQMDK Oncology Antibodies Demonstrate In-Vivo Safety Development milestone achieved Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high growth, high value oncology market is pleased to announce the ROQ-A1 and ROQ-A2 Midkine ("MDK") antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in pre-clinical development programs carried out by leading cancer research groups. As stated in the Company's announcement of 9 January 2023, Roquefort Therapeutics has recently signed partnership agreements and commenced pre-clinical development programs with leading academic cancer research groups at the Olivia Newton-John Cancer Research Institute (La Trobe University), Lowry Cancer Research Centre (University of New South Wales), Hawkins Laboratory Biochemistry and Genetics (La Trobe University) and the School of Medical Sciences (University of Sydney). ROQ-A1 and ROQ-A2 are the latest patented humanised antibody medicines designed by Roquefort Therapeutics to target the novel MDK target prevalent in hard-to-treat cancers. In laboratory experiments, ROQ-A1 and ROQ-A2 bind highly specifically to the MDK receptors in cancer cells to kill cancers in vitro. The MDK antibody programs targeting metastatic breast cancer and metastatic lung cancer commenced in Q4 2022 at La Trobe University, Melbourne in the Olivia Newton-John Cancer Research Institute and Hawkins Laboratory respectively and have now successfully reached the first pre-clinical drug development milestone. Metastatic breast cancer and metastatic lung cancer were chosen because of high patient mortality rates (~70% at five years) and prevalence of resistant MDK subtypes which can reduce effectiveness of existing therapies. Therefore, Roquefort Therapeutics is pleased that both ROQ-A1 and ROQ-A2 have demonstrated a good safety profile in validated in vivo models. These milestones were completed on schedule and within budget. Both MDK antibody programs will now progress into in vivo pre-clinical efficacy studies to assess cancer killing ability in primary and metastatic breast cancer and lung cancer. The Company will update the market on the results of these efficacy studies as they progress. Ajan Reginald, Chief Executive Officer of Roquefort Therapeutics, said: "We have started 2023 with significant momentum successfully completing these initial pre-clinical development milestones on schedule and within budget. The ROQ-A1 and ROQ-A2 antibodies are valuable assets that fit the established Big Pharma paradigm of treating cancer with novel antibody therapeutics. Therefore, we are pleased that both programs have shown the good safety profile that is particularly attractive for innovative cancer medicines targeting novel targets such as Midkine. Both programs will now progress rapidly into in vivo pre-clinical efficacy testing. The siRNA, MK cell therapy and Midkine oligonucleotide programs are also progressing well and are expected to complete development milestones in Q1, which we will update the market on in due course." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
